Which of the following are correct classifications of lupus nephritis: diffuse proliferative, membranous, IgA nephropathy, membranoproliferative glomerulonephritis, or focal proliferative?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Classification of Lupus Nephritis

The correct classifications of lupus nephritis from the options provided are: a) Diffuse proliferative, b) Membranous, and e) Focal proliferative. IgA nephropathy and membranoproliferative glomerulonephritis are NOT part of the standard lupus nephritis classification system 1, 2, 3.

The ISN/RPS Classification System

The International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification is the current standard for categorizing lupus nephritis 4, 1. This system includes six classes:

Valid Lupus Nephritis Classes:

  • Class I: Minimal mesangial lupus nephritis (mesangial immune deposits without hypercellularity)
  • Class II: Mesangial proliferative lupus nephritis (mesangial immune deposits with hypercellularity)
  • Class III: Focal proliferative lupus nephritis (involving <50% of glomeruli) - CORRECT ANSWER (e)
  • Class IV: Diffuse proliferative lupus nephritis (involving ≥50% of glomeruli) - CORRECT ANSWER (a)
  • Class V: Membranous lupus nephritis (subepithelial immune deposits) - CORRECT ANSWER (b)
  • Class VI: Advanced sclerosing lupus nephritis (≥90% glomerular sclerosis)

2, 3

Why the Other Options Are Incorrect

IgA Nephropathy (Option c) - INCORRECT

IgA nephropathy is not a classification of lupus nephritis. It is a distinct primary glomerulonephritis characterized by dominant mesangial IgA deposition 5, 6. While IgA nephropathy can rarely coexist with SLE as a separate entity, this represents either coincidental occurrence or a secondary phenomenon—not a lupus nephritis class 5, 6.

Critical pitfall: When IgA-dominant deposits are found in an SLE patient, this typically indicates primary IgA nephropathy occurring alongside SLE rather than lupus nephritis itself. The key distinguishing feature is the absence of IgG and C1q deposits, which are hallmarks of true lupus nephritis 5.

Membranoproliferative Glomerulonephritis (Option d) - INCORRECT

Membranoproliferative glomerulonephritis (MPGN) is not a classification of lupus nephritis. While lupus nephritis can occasionally exhibit an MPGN-like histologic pattern (with double-contoured basement membranes and subendothelial deposits), this is a descriptive finding within existing classes (particularly Class IV) rather than a separate classification category 7.

Key Diagnostic Considerations

The ISN/RPS classification requires evaluation by:

  • Light microscopy for proliferative changes and distribution
  • Immunofluorescence for immune deposit characterization (IgG, IgM, IgA, C1q, C3)
  • Electron microscopy for deposit location (subendothelial, subepithelial, mesangial)

1, 2

Classes III and IV require aggressive immunosuppression with glucocorticoids and immunosuppressive agents, while Class V alone may be approached differently 1. The distinction between focal (<50%) and diffuse (≥50%) glomerular involvement is therapeutically critical, as it directly impacts treatment intensity and prognosis.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.